^
BIOMARKER:

BCR-ABL1 T315I

i
Other names: ABL proto-oncogene 1, ABL, c-ABL, JTK7, p150, ABL1, BCR, BCR Activator Of RhoGEF And GTPase, BCR, RhoGEF And GTPase Activating Protein, Breakpoint Cluster Region Protein, Renal Carcinoma Antigen NY-REN-26, Breakpoint Cluster Region, D22S11, BCR1, BCR/FGFR1 Chimera Protein, FGFR1/BCR Chimera Protein, D22S662, ALL, CML, PHL
Entrez ID:
BCR-ABL1 T315I
CML
ponatinib
Sensitive: A1 - Approval
BCR-ABL1 T315I
ALL
ponatinib
Sensitive: A1 - Approval
BCR-ABL1 T315I
ALL
dasatinib
Resistant: A2 - Guideline
BCR-ABL1 T315I
ALL
bosutinib
Resistant: A2 - Guideline
BCR-ABL1 T315I
ALL
nilotinib
Resistant: A2 - Guideline
BCR-ABL1 T315I
CML
dasatinib
Resistant: A2 - Guideline
BCR-ABL1 T315I
CML
bosutinib
Resistant: A2 - Guideline
BCR-ABL1 T315I
CML
nilotinib
Resistant: A2 - Guideline
BCR-ABL1 T315I
CML
ABL001
Sensitive: B - Late Trials
BCR-ABL1 T315I
CML
HQP1351
Sensitive: B - Late Trials
BCR-ABL1 T315I
B Acute Lymphoblastic Leukemia
ponatinib
Sensitive: C1 - Off-label
BCR-ABL1 T315I
B Acute Lymphoblastic Leukemia
T-lymphocyte cell therapy
Sensitive: C3 – Early Trials
BCR-ABL1 T315I
CML
imatinib
Resistant: C3 – Early Trials
BCR-ABL1 T315I
CML
dasatinib + nilotinib
Resistant: C3 – Early Trials
BCR-ABL1 T315I
CML
PF-114
Sensitive: C3 – Early Trials
BCR-ABL1 T315I
CML
axitinib
Sensitive: C4 – Case Studies
BCR-ABL1 T315I
CML
dasatinib + axitinib
Sensitive: C4 – Case Studies
BCR-ABL1 T315I
NHL
imatinib
Sensitive: C4 – Case Studies
BCR-ABL1 T315I
CML
NT-157
Sensitive: D – Preclinical
BCR-ABL1 T315I
CML
sorafenib
Sensitive: D – Preclinical
BCR-ABL1 T315I
CML
CUDC-907
Sensitive: D – Preclinical
BCR-ABL1 T315I
CML
ponatinib + GMX1778
Sensitive: D – Preclinical
BCR-ABL1 T315I
Leukemia
ponatinib + ABL001
Sensitive: D – Preclinical
BCR-ABL1 T315I
B Acute Lymphoblastic Leukemia
IODVA1
Sensitive: D – Preclinical